Allergy Shots for Asthma: Symptom Relief Yes, Lung Function Maybe Not
Allergy shots meaningfully reduce allergic asthma symptoms (SMD -0.59) and medication use (SMD -1.21) with NNT of 3-4, but do not consistently improve FEV1 across the overall evidence base. HDM-monosensitized patients show FEV1 improvement of +5.37%. FEV1 below 70% predicted is a contraindication. Four of 7 SCIT fatalities from 2013-2017 involved patients with asthma, making disease control essential before each injection.
8 peer-reviewed sources
Allergy shots reduce asthma symptoms and medication use significantly, but most evidence shows no consistent improvement in lung function (FEV1). Uncontrolled asthma with FEV1 below 70% predicted is a contraindication for SCIT.
Key facts
A 2026 observational cohort of 2,897 patients on at-home sublingual immunotherapy reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, showing how benefit accrues with time on treatment rather than arriving early.
Allergy Shots for Asthma: An Honest Assessment of What the Evidence Shows
Allergy shots (SCIT) can meaningfully reduce allergic asthma symptoms and cut rescue medication use — but they tell only part of the story that patients need to hear. The Cochrane review of 88 asthma SCIT trials found symptom score reductions equivalent to a standardized mean difference (SMD) of -0.59 and medication reductions of SMD -1.21, with a number needed to treat of 3 to prevent one symptom deterioration and 4 to prevent one increase in asthma medications. Those are clinically meaningful numbers.
What the same evidence base consistently does NOT show is improvement in FEV1 — the most objective measure of lung function. Across the broad asthma SCIT literature, FEV1 improvements have not reached statistical or clinical significance. The exception is a specific subset: HDM-monosensitized asthma patients show FEV1 improvement of +5.37% predicted (Zheng et al., 2023), a finding that informs who is most likely to benefit from asthma-directed SCIT.
Before pursuing SCIT for asthma, confirming which allergens are driving sensitization is essential — treatment that targets allergens you are not clinically sensitized to will not produce benefit. Comprehensive allergy testing through Curex's at-home kits can identify specific IgE-mediated triggers, determining whether an allergen-driven component to the asthma is present and which specific extracts should be targeted.
SCIT reduces asthma symptoms and medication use with NNT of 3-4, but does not reliably improve FEV1 overall. Uncontrolled asthma (FEV1 <70% predicted) is a contraindication. HDM-monosensitized patients may see lung function benefits as well.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
What Allergy Shots Do (and Don't Do) for Asthma
The Abramson Cochrane Review (2010, 88 RCTs, approximately 3,500 patients) remains the definitive evidence synthesis for SCIT in allergic asthma. Its conclusions are precise: asthma symptoms improve significantly, medication burden falls significantly, but FEV1 does not change consistently across the broad evidence base. For HDM-driven asthma specifically, more recent meta-analyses identify a lung-function benefit that is absent in the broader mixed-allergen literature. For patients with allergic asthma seeking to start immunotherapy without weekly clinic visits, Curex at-home allergy shots (pricing confirmed in a current program quote) apply the same SCIT protocol — addressing HDM, pollen, and other triggers confirmed by IgE testing — as a once-weekly home injection. The first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff; a prescribed epinephrine auto-injector is confirmed on hand before starting, and asthma control is assessed by the care team before each dose cycle. The safety rationale for this at-home model is supported by a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015), which found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
Success Rate by Duration
Same proven results. No clinic visits.
Curex at-home allergy shots are clinician-supervised; confirm your current program quote before enrolling.
Join the waitlistCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
Why Asthma Is the Most Important SCIT Safety Variable
Asthma is not just a comorbidity for patients receiving allergy shots — it is the single most important risk factor for severe and fatal reactions. The AAAAI/ACAAI surveillance data from 2013-2017 identified 4 of 7 SCIT fatalities in patients with asthma, most with suboptimally controlled disease. The mechanism is clear: pre-existing airway hyperreactivity amplifies the bronchospastic response to mast-cell mediators, and reduced respiratory reserve accelerates hypoxic decompensation when reactions do occur.
Patients with well-controlled allergic asthma — FEV1 at or above 70% predicted, minimal rescue inhaler use, no recent exacerbations — can receive allergy shots following standard protocols. Asthma control should be formally assessed before every injection, not just at enrollment. The 30-minute post-injection observation period is especially important for asthmatic patients.
Pre-injection peak flow or spirometry assessment. Continue asthma controller medications as prescribed. Report any asthma worsening between visits to your allergist immediately.
Intercurrent respiratory infections, allergen exposure during pollen season, or medication changes can temporarily worsen asthma control during an otherwise successful SCIT program. Any visit at which asthma is acutely worse than baseline should prompt postponement of the injection until control is re-established. Many US allergists reduce SCIT doses during peak allergen season for asthmatic patients.
Postpone injection if asthma is poorly controlled at time of visit. Contact prescribing physician to reassess asthma controller regimen before resuming SCIT.
Mild bronchospasm — wheeze, cough, or chest tightness occurring within 30-60 minutes of injection — represents a lower-respiratory systemic reaction (WAO Grade 2 or 3). Asthmatic patients are at higher risk for this response compared to non-asthmatic SCIT patients. Bronchospasm responsive to a rescue bronchodilator is Grade 2; bronchospasm with more than 40% PEF/FEV1 drop not responding to bronchodilator is Grade 3.
Administer rescue bronchodilator (albuterol) immediately. Notify your care team — on a Virtual Shot Room–supervised dose your allergist directs management in real time. Administer epinephrine if bronchospasm does not respond to two bronchodilator treatments — do not delay epinephrine for Grade 3 reactions. Call 911 if not improving.
The most dangerous SCIT reactions in asthmatic patients involve respiratory failure due to combined upper and lower airway obstruction. This presentation — bronchospasm plus laryngospasm or throat edema — can escalate rapidly in patients with pre-existing airway hyperreactivity. Fatal outcomes in asthmatic SCIT patients have been associated with delayed epinephrine administration and inadequate pre-injection asthma control assessment.
Administer epinephrine intramuscularly immediately. Call 911. Do not substitute antihistamines or steroids for epinephrine — they are too slow. Inhaled albuterol can be used as adjunctive therapy alongside epinephrine for bronchospasm, not instead of it.
When to Worry: Decision Guide
Is your asthma well controlled today (FEV1 ≥70%, no recent exacerbation, minimal rescue inhaler use)?
Proceed with injection
Confirm with your care team. Receive injection. Observe for full 30 minutes.
Do not receive injection today
Contact prescribing physician. Do not receive SCIT injection when asthma is poorly controlled.
Frequently asked questions
Do allergy shots improve lung function in asthma?
The overall evidence base for allergy shots and lung function in asthma is mixed. The Abramson Cochrane Review (2010, 88 RCTs) found no consistent improvement in FEV1 across all allergen types and populations. However, when the analysis is narrowed to HDM-monosensitized asthmatic patients, a meaningful lung function benefit emerges: Zheng et al.'s 2023 meta-analysis found FEV1 improvement of +5.37% predicted (95% CI 1.18-9.57%) in this specific subset. Bronchial hyperreactivity to specific allergen challenge does improve across the broader literature, even when non-specific FEV1 does not. The honest framing for patients: allergy shots are likely to reduce asthma symptoms and medication use, but should not be chosen primarily for FEV1 improvement unless you are HDM-monosensitized.
Can allergy shots reduce asthma medication use?
Yes, this is one of the most consistent findings in the asthma SCIT literature. The Abramson Cochrane Review (2010, 88 RCTs) found medication use reduction with a standardized mean difference of -1.21 — a clinically substantial effect size. Translated into the NNT framework, approximately 4 patients must be treated with SCIT to prevent one patient from needing increased asthma medications. In the HDM asthma cohort specifically, Zheng et al. (2023) found medication SMD of -1.04. Real-world German insurance data (Fritzsching, JACI 2022) confirmed lasting improvement in asthma control and lower medication use in SCIT-treated patients versus matched non-AIT controls, with benefits growing after AIT cessation.
What is the FEV1 threshold for getting allergy shots with asthma?
Most major guidelines use FEV1 below 70% of predicted as the threshold at which allergy shots should be withheld or used with extreme caution. The AAAAI/ACAAI Practice Parameter recommends assessing FEV1 before each injection and withholding the injection if asthma is uncontrolled. GINA 2023 and EAACI 2018 similarly specify that SCIT should not be initiated until asthma is well controlled. The 70% threshold is not absolute — clinical judgment matters — but it represents the consensus safety boundary supported by surveillance data showing that uncontrolled asthma is the dominant risk factor for severe and fatal SCIT reactions.
How does at-home SCIT compare to SLIT for allergic asthma?
For HDM-sensitized patients with asthma, both SCIT and SLIT have supporting evidence, and GINA 2024 endorses HDM SLIT as an add-on therapy when FEV1 exceeds 70% predicted. The Virchow et al. JAMA 2016 trial (n=834) is the strongest SLIT asthma trial, showing a 31% reduction in moderate-severe asthma exacerbations during ICS reduction in HDM-sensitized patients. SCIT has a larger symptom and medication reduction effect size overall (SMD -0.59 and -1.21 vs. SLIT's comparable but slightly smaller effects). Curex at-home SCIT closes the historical convenience gap: a once-weekly home injection removes clinic commutes, while the Virtual Shot Room–supervised first dose, prescribed epinephrine auto-injector, and USP <797>-compounded serum provide the safety infrastructure that made in-clinic SCIT the prior standard. For patients with needle concern, HDM SLIT tablets (Odactra) remain an evidence-backed single-allergen option when HDM is the dominant sensitization.
Can allergy shots prevent asthma in people with allergic rhinitis?
Evidence suggests yes, particularly in children, though formal asthma-prevention evidence is stronger for pediatric SCIT (PAT study) than for adult primary prevention. The PAT study showed SCIT cut the risk of asthma development by roughly half in children with allergic rhinoconjunctivitis (OR 2.52, with benefit persisting 7 years post-treatment). For adults with allergic rhinitis, large observational studies (Schmitt et al., JACI 2015, n=118,000) show allergy immunotherapy is associated with reduced asthma incidence versus matched non-treated controls. Prevention of the allergic march from rhinitis to asthma is one of the most compelling arguments for early immunotherapy intervention, particularly in children.
What type of asthma responds best to allergy shots?
Allergic asthma driven by a single dominant allergen (monosensitization) responds better to SCIT than polysensitized asthma. HDM-monosensitized patients show the most consistent lung function improvement (+5.37% FEV1 in Zheng's 2023 meta-analysis), while polysensitized asthmatic patients show more variable responses. Mild to moderate allergic asthma with confirmed IgE-mediated sensitization to environmental allergens is the ideal indication — this is the patient population in which all major guidelines (EAACI, GINA, AAAAI/ACAAI) support SCIT as an add-on therapy. Non-allergic asthma, severe uncontrolled asthma, and asthma with FEV1 persistently below 70% do not meet criteria for SCIT initiation.
Related Articles
Allergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT retrains the immune system over 3–5 years and is the only disease-modifying allergy treatment; many patients get long-term relief that can persist after treatment.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.